These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 16972714)

  • 1. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: general concepts.
    Bretz F; Schmidli H; König F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):623-34. PubMed ID: 16972714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: opportunities and limitations.
    Jenniso C; Turnbull BW
    Biom J; 2006 Aug; 48(4):650-5; discussion 660-2. PubMed ID: 16972717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How practical are adaptive designs likely to be for confirmatory trials?
    Gould AL
    Biom J; 2006 Aug; 48(4):644-9; discussion 660-2. PubMed ID: 16972716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plan to be flexible: a commentary on adaptive designs.
    Shih WJ
    Biom J; 2006 Aug; 48(4):656-9; discussion 660-2. PubMed ID: 16972718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Confirmatory seamless phase II/III clinical trials with hypotheses selection at interim: applications and practical considerations.
    Schmidli H; Bretz F; Racine A; Maurer W
    Biom J; 2006 Aug; 48(4):635-43. PubMed ID: 16972715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Practical guidelines for adaptive seamless phase II/III clinical trials that use Bayesian methods.
    Kimani PK; Glimm E; Maurer W; Hutton JL; Stallard N
    Stat Med; 2012 Aug; 31(19):2068-85. PubMed ID: 22437262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statistical aspects of the TNK-S2B trial of tenecteplase versus alteplase in acute ischemic stroke: an efficient, dose-adaptive, seamless phase II/III design.
    Levin B; Thompson JL; Chakraborty B; Levy G; MacArthur R; Haley EC
    Clin Trials; 2011 Aug; 8(4):398-407. PubMed ID: 21737464
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A confirmatory seamless phase II/III clinical trial design incorporating short-term endpoint information.
    Stallard N
    Stat Med; 2010 Apr; 29(9):959-71. PubMed ID: 20191605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Group-sequential methods for adaptive seamless phase II/III clinical trials.
    Stallard N
    J Biopharm Stat; 2011 Jul; 21(4):787-801. PubMed ID: 21516569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose selection in seamless phase II/III clinical trials based on efficacy and safety.
    Kimani PK; Stallard N; Hutton JL
    Stat Med; 2009 Mar; 28(6):917-36. PubMed ID: 19152231
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conditionally unbiased estimation in phase II/III clinical trials with early stopping for futility.
    Kimani PK; Todd S; Stallard N
    Stat Med; 2013 Jul; 32(17):2893-910. PubMed ID: 23413228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmatory clinical trials with an adaptive design.
    Koch A
    Biom J; 2006 Aug; 48(4):574-85. PubMed ID: 16972708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing the data combination rule for seamless phase II/III clinical trials.
    Hampson LV; Jennison C
    Stat Med; 2015 Jan; 34(1):39-58. PubMed ID: 25315892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of methods for constructing confidence intervals after phase II/III clinical trials.
    Kimani PK; Todd S; Stallard N
    Biom J; 2014 Jan; 56(1):107-28. PubMed ID: 24173686
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of methods for adaptive treatment selection.
    Friede T; Stallard N
    Biom J; 2008 Oct; 50(5):767-81. PubMed ID: 18932136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An adaptive two-stage design with treatment selection using the conditional error function approach.
    Wang J
    Biom J; 2006 Aug; 48(4):679-89. PubMed ID: 16972720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An alternative phase II/III design for continuous endpoints.
    Huang WS; Liu JP; Hsiao CF
    Pharm Stat; 2011; 10(2):105-14. PubMed ID: 20186724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A seamless phase II/III design with sample-size re-estimation.
    Bischoff W; Miller F
    J Biopharm Stat; 2009 Jul; 19(4):595-609. PubMed ID: 20183428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response adaptive randomization procedures in seamless phase II/III clinical trials.
    Zhu H; Piao J; Lee JJ; Hu F; Zhang L
    J Biopharm Stat; 2020; 30(1):3-17. PubMed ID: 31454295
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.